Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Clinical trial NCT00113802 · TERMINATED
Trial details
- NCT number
- NCT00113802
- Sponsor
- Gilead Sciences
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-08-01
- Primary completion
- 2006-12-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.